Maud Vaillant-Maho
Rouen, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.
Journal: The Journal of investigative dermatology
Published: May 18, 2026
Cellular and Cytokine Responses of Corneal Fibroblasts Exposed to Keratopigmentation Inks in Vitro.
Journal: Experimental eye research
Published: January 03, 2026
Tocilizumab for severe and refractory mucous membrane pemphigoid.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 04, 2025
Prevalence and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus.
Journal: The British journal of dermatology
Published: November 06, 2025
Persistence of anti-Desmoglein 3 Antibodies in Patients with Pemphigus Vulgaris in Clinical Remission is Associated with Restricted Isotype Diversity and Desmoglein 3 Ectodomain Recognition.
Journal: The British journal of dermatology
Published: October 23, 2025
Incidence of P200 pemphigoid: A nationwide study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 11, 2025
Prevalence and pathogenic activity of anti-desmocollin-3 antibodies in patients with pemphigus vulgaris and pemphigus foliaceus.
Journal: The British journal of dermatology
Published: March 07, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
Journal: JAMA dermatology
Published: January 24, 2024
The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.
Journal: The British journal of dermatology
Published: May 16, 2023
IgG N-Glycosylation from Patients with Pemphigus Treated with Rituximab.
Journal: Biomedicines
Published: May 25, 2022
Last Updated: 09/26/2026